1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. LILLY(ELI) & CO
Lilly(Eli) & Co
XNYS: LLY
Mid-range Performer
Download real time
1188.7231.23(2.70%)
51.65% Gain from 52W Low
2.3M
XNYS Volume

XNYS 07 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Eli Lilly quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Eli Lilly share price target, revenues, EPS, net income and more

Eli Lilly quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • POSITIVE

    Quarterly Revenue Eli Lilly Jun-2026 Quarterly Revenue is $22,974 Million which is growth of 47.7% YoY.

  • POSITIVE

    Quarterly Net Profit Eli Lilly Jun-2026 Quarterly Net Profit is $7,095 Million which is growth of 25.3% YoY.

Lilly(Eli) & Co, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
22,97419,79919,29217,600.815,557.712,728.513,532.811,439.111,302.88,7689,353.49,498.68,312.1
Cost Of Rev.
3,2683,5773,371.73,008.32,447.82,224.22,403.82,170.82,170.21,673.51,7881,860.11,807.4
Gross Profit
19,70616,22215,920.314,592.513,109.910,504.311,1299,268.39,132.67,094.57,565.47,638.56,504.7
⌄
7,2496,4446,932.96,206.46,089.15,202.55,4474,833.94,828.54,4754,487.34,2134,281.9
Operating Profit
12,4579,7788,987.48,386.17,020.85,301.85,6824,434.44,304.12,619.53,078.13,425.52,222.8
⌄
-274-253-123-114.6-209-195.4-180.4-144.9-146.3-133.8-93.7-75.7-74.3
Profit Before Tax
9,2478,8508,266.27,232.46,776.43,456.15,038.71,588.43,517.22,536.12,508.8427.22,088.9
Tax
2,1521,4541,628.51,649.91,115.9696.8628.9618.1550.2293.2319.1484.6325.7
⌄
7,0957,3966,637.75,582.55,660.52,759.34,409.8970.32,9672,242.92,189.7-57.41,763.2
Diluted NI Avail to Com Stockholders Ann.
7,0957,3966,637.75,582.55,660.52,759.34,409.8970.32,9672,242.92,189.7-57.41,763.2
Basic EPS
88.37.46.26.33.14.91.13.32.52.4-0.12
Diluted EPS After ExtraOrdinary
10.99.187.16.34.65.4342.632.52.1
Number Of Shares End
892.4894.5895.8896.9897.9898.7899.7901900.9900.8900.1899.8899.7
Net Income Continuing Discontinued Operations
7,0957,3966,637.75,582.55,660.52,759.34,409.8970.32,9672,242.92,189.7-57.41,763.2
Normalized Income
9,764.48,117.27,141.26,334.15,693.84,158.54,8942,678.43,597.62,326.42,686.32,197.71,899.9
Interest Income
---654048.344.347.837.345.844.548.946
Interest
---179.6249243.7224.7192.7183.6179.6138.2124.6120.3
Net Interest Income
-274-253-123-114.6-209-195.4-180.4-144.9-146.3-133.8-93.7-75.7-74.3
EBIT
12,4579,77811,558.87,4127,025.43,699.85,263.41,781.13,700.82,715.72,647551.82,209.2
EBITDA
12,99110,28712,144.57,8827,503.94,162.65,748.22,247.94,115.23,116.33,034.7962.82,575.5
Reconciled Cost Of Rev.
3,2683,5773,371.73,008.32,447.82,224.22,403.82,170.82,170.21,673.51,7881,860.11,807.4
Reconciled Depr.
534509585.7470478.5462.8484.8466.8414.4400.6387.7411366.3
Profit From Continuing Operations
7,0957,3966,637.75,582.55,660.52,759.34,409.8970.32,9672,242.92,189.7-57.41,763.2
Normalized EBITDA
16,47011,15012,771.58,855.77,543.75,9166,301.45,043.54,862.43,210.83,603.74,000.82,737.5
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Eli Lilly competitor comparison and performance snapshot within industry

Eli Lilly annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Annual Revenue Eli Lilly Dec-2025 Annual Revenue is $65,179 Million which is growth of 44.7% YoY.

  • POSITIVE

    Annual Net Profit Eli Lilly Dec-2025 Annual Net Profit is $20,640 Million which is growth of 94.9% YoY.

Lilly(Eli) & Co, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
31.7%
21.6%
 65,17945,042.734,124.128,541.428,318.424,539.822,319.524,555.722,871.321,222.119,958.7
Cost Of Rev. Ann.
18.6%
15%
13,22511,0528,418.37,082.26,629.87,312.85,483.34,721.26,4306,070.25,654.95,037.2
Gross Profit Ann.
35.2%
23.2%
66,440.854,12736,624.427,041.921,911.621,005.619,056.517,598.318,125.716,801.115,567.214,921.5
Operating Exp. Ann.
21.5%
14.9%
26,832.324,43119,584.416,716.513,631.213,457.512,206.911,808.811,938.912,383.611,695.911,329.4
Operating Profit Ann.
53.1%
34.1%
39,608.529,69617,04010,325.48,280.47,548.16,849.65,789.56,186.84,417.53,871.33,592.1
⌄
-
-
-764.6-642-605.4-312.3-268.8-314.4-326.6-320.2-110.8-57.7-76.5-74.2
Other Exp. Ann.
-
-
 -3,965-3,754.2-3,458.5-1,205.2-1,078.2706.9-203.4-2,280.3-2,162.4-420.8-727.9
PBT Ann.
55.8%
28.9%
33,595.625,73112,680.46,554.66,806.46,155.57,229.95,265.93,795.72,197.43,3742,790
Tax Ann.
108.5%
37.5%
6,884.45,0912,090.41,314.2561.6573.81,036.2628563.72,401.5636.4381.6
⌄
49%
27.2%
26,711.220,64010,5905,240.46,244.85,581.76,193.78,318.43,232-204.12,737.62,408.4
Diluted NI Avail to Com Stockholders Ann.
49%
27.2%
26,711.220,64010,5905,240.46,244.85,581.76,193.78,318.43,232-204.12,737.62,408.4
EPS Ann.
49.4%
27.6%
 2311.85.86.96.26.88.93.1-0.22.62.3
Diluted EPS Ann.
49.4%
27.6%
 2311.75.86.96.16.88.93.1-0.22.62.3
Number Of Shares End
-0.2%
-0.3%
 895.8899.7900.1901.5904.8908909.61,011.31,043.71,058.11,060.5
Total Exp. Ann.
20.5%
14.9%
 35,48328,002.723,798.720,26120,770.317,690.216,53018,368.918,453.817,350.816,366.6
Net Income Continuing Discontinued Operations Ann.
49%
27.2%
26,711.220,64010,5905,240.46,244.85,581.76,193.78,318.43,232-204.12,737.62,408.4
Normalized Income Ann.
44.9%
27.7%
31,356.823,362.514,089.18,346.77,678.86,8696,872.15,305.65,330.51,159.43,237.53,331.3
Interest Income Ann.
-
-
 -175.2173.662.825.43380.4161.3167.3108.787
Interest Ann.
-
-
 -780.6485.9331.6339.8359.6400.6272.1225185.2161.2
EBITDA Ann.
54.1%
28.9%
43,304.531,69315,227.68,567.88,660.58,042.98,913.46,899.15,676.83,989.75,055.84,378.9
Reconciled Cost Of Rev. Ann.
18.6%
15%
13,22511,0528,418.37,082.26,629.87,312.85,483.34,721.26,4306,070.25,654.95,037.2
Reconciled Depr. Ann.
9.5%
8.6%
2,098.71,9971,766.61,527.31,522.51,547.61,323.91,232.61,6091,567.31,496.61,427.7
Profit From Continuing Operations Ann.
49%
27.2%
26,711.220,64010,5905,240.46,244.85,581.76,193.78,318.43,232-204.12,737.62,408.4
Normalized EBITDA Ann.
50.8%
29.3%
49,247.235,08719,418.112,455.510,224.39,462.29,7057,6578,142.76,262.25,672.25,448.3
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
44.7%
2Y CAGR
38.2%
3Y CAGR
31.7%
5Y CAGR
21.6%
7Y CAGR
15%
10Y CAGR
12.6%
Total Revenue Annual growth is higher than historical averages.
Net Profit Ann.
1Y CHG
94.9%
2Y CAGR
98.5%
3Y CAGR
49%
5Y CAGR
27.2%
7Y CAGR
30.3%
10Y CAGR
24%
Net Profit Annual growth is higher than historical averages.
Operating Exp. Ann.
1Y CHG
24.7%
2Y CAGR
20.9%
3Y CAGR
21.5%
5Y CAGR
14.9%
7Y CAGR
10.8%
10Y CAGR
8%
Operating Expenses Annual Cr growth is higher than historical averages.

Eli Lilly balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Total Shareholders Fund Eli Lilly Dec-2025 Total Shareholders Fund is $26,535 Million which is growth of 87.0% YoY.

  • POSITIVE

    Total Assets Eli Lilly Dec-2025 Total Assets is $112,476 Million which is growth of 42.9% YoY.

Lilly(Eli) & Co, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
31.5%
19.3%
112,47678,714.964,006.349,489.848,80646,633.139,286.143,908.444,98138,805.935,568.9
⌄
30.4%
16.1%
85,94164,443.353,142.638,714.439,651.240,807.936,58732,999.333,313.124,725.420,978.6
⌄
35.6%
36.3%
26,53514,192.110,771.910,649.88,979.25,641.62,606.99,828.711,592.214,007.714,571.3
Total Capitalization Ann.
38.5%
24.8%
67,40342,719.229,092.725,387.324,325.622,228.216,424.821,468.421,532.722,375.522,543.7
Tangible Assets Ann.
-
-
14,1152,255.5-1,074.4-629.8-2,604.7-5,574.9-7,690.51,960.23,192.95,677.15,496.6
Working Capital Ann.
183.4%
32.6%
20,4014,363.1-1,566.2896.33,399.74,980.51,934.48,661.54,666.24,114.84,344
Invested Capital Ann.
36.9%
25.4%
69,03847,836.335,997.226,888.425,863.922,236.917,924.122,599.625,239.324,312.922,549.8
Tangible Book Value Ann.
-
-
14,1152,255.5-1,074.4-629.8-2,604.7-5,574.9-7,690.51,960.23,192.95,677.15,496.6
Borrowings Ann.
37.8%
20.7%
42,50333,644.225,225.316,238.616,884.716,595.315,803.912,770.913,647.110,305.27,978.5
Net Debt Ann.
35.5%
22.2%
35,23530,375.822,406.714,171.613,066.212,938.212,979.74,772.77,110.95,723.14,312.1
Share Issued Ann.
-0.2%
-0.3%
944.8947.9949.8950.6954.1957.1958.11,057.61,100.71,101.61,106.1
Number Of Shares End
-0.2%
-0.3%
895.8899.7900.1901.5904.8908909.61,011.31,043.71,058.11,060.5
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
42.9%
2Y CAGR
32.6%
3Y CAGR
31.5%
5Y CAGR
19.3%
7Y CAGR
14.4%
10Y CAGR
12.2%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
1Y CHG
24.1%
2Y CAGR
13.6%
3Y CAGR
27.1%
5Y CAGR
23.1%
7Y CAGR
16.8%
10Y CAGR
15.7%
Total Current Liabilities Annual Cr growth is stable compared to historical averages.
Total ShareHolders Funds Ann.
1Y CHG
87%
2Y CAGR
57%
3Y CAGR
35.6%
5Y CAGR
36.3%
7Y CAGR
15.2%
10Y CAGR
6.2%
Total ShareHolders Funds Annual growth is higher than historical averages.

Eli Lilly ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Book Value Per Share Eli Lilly Book Value Per Share is $38 which is growth of 86.5% YoY.

  • NEUTRAL

    ROE Eli Lilly ROE is 0% which is growth of 0% YoY.

Lilly(Eli) & Co, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
RoA Ann. %
-
-
-14.84%9.23%12.71%11.70%14.42%20.00%7.27%-0.49%7.36%6.62%
ROE Ann. %
-
-
-84.84%48.93%63.63%76.35%150.18%133.78%30.18%-1.59%19.16%16.09%
ROIC %
-
-
-9.86.77.57.1108.44.8-6.23.22.1
OPM Ann. %
16.2%
10.3%
45.56%37.83%30.26%29.01%26.65%27.91%25.94%25.19%19.31%18.24%18.00%
Inventory Turnover Ratio Ann.
-
-
-1.31.41.61.91.51.31.51.51.61.6
Asset Turnover Ann. %
-
-
-0.60.60.60.60.60.50.60.60.60.6
Working Capital Turnover Ann.
-53.5%
-8.2%
3.210.3-21.831.88.34.911.52.84.95.24.6
Quick Ratio Ann.
-
-
-0.60.50.60.80.90.71.20.911
Current Ratio Ann.
-
-
-1.20.91.11.21.41.21.71.31.41.5
Interest Coverage Ratio Ann.
-
-
-17.214.521.519.121.114.21510.819.218.3
LT Debt To Equity Ann.
-
-
-21.71.41.72.95.51.20.90.60.6
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Eli Lilly cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Cash From Operating Activity Eli Lilly Dec-2025 Cash From Operating Activity is $16,813 Million which is growth of 90.7% YoY.

  • POSITIVE

    Net Cash Flow Eli Lilly Dec-2025 Net Cash Flow is $3,628 Million which is growth of 386.0% YoY.

Lilly(Eli) & Co, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
33.4%
20.9%
16,8138,817.94,240.17,084.47,260.76,499.64,836.65,524.55,615.64,8512,772.8
⌄
-
-
-10,972-9,301.5-7,152.7-3,261.6-2,762.3-2,258.9-8,082.91,906-3,783.6-3,139.126.8
⌄
-
-
-2,2131,230.13,495.6-5,406.7-4,131.3-3,137.1-2,324.5-5,904.9142.6-559.8-2,919.2
Cash Plus Cash Eqv. End Of Year Ann.
52.1%
14.7%
7,2683,268.42,818.62,0673,818.53,657.12,337.57,998.26,536.24,582.13,666.4
Net Increase In Cash Plus Cash Eqv.s Ann.
-
26.9%
3,628746.5583-1,583.9367.11,103.6-5,570.81,525.61,974.61,152.1-119.6
Cash Plus Cash Eqv. Begin Of Year Ann.
-5.1%
6.9%
3,2682,818.62,0673,818.53,657.12,337.57,998.26,536.24,582.13,666.43,871.6
Income Tax Paid Supplemental Data Ann.
-
-
-----------
Interest Paid Supplemental Data Ann.
-
-
-----------
Capex Ann.
-
-
-10,849-8,403.6-7,392.1-2,484-1,873.2-2,029.1-1,353.5-3,018.2-2,163.6-1,092-1,626.2
Issuance Of Capital Stock Ann.
-
-
-----1,659.7---
Issuance Of Debt Ann.
-
44.9%
13,16711,417.13,958.52,410.82,062.36,556.42,477.72,2321,206.64,454.7
Repayment Of Debt Ann.
-
-
-778-664.2-1,560-1,905.4-276.5-2,866.4-1,009.1-630.6-0.2-1,955.7
Repurchase Of Capital Stock Ann.
-
-
-4,108-2,500-750-1,500-1,250-500-4,400-4,150.7-299.8-600.1-749.5
Free Cash Flow Ann.
9%
5.9%
5,964414.3-3,1524,600.45,387.54,470.53,483.12,506.33,4523,7591,146.6
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Operating Act. Ann.
1Y CHG
90.7%
2Y CAGR
99.1%
3Y CAGR
33.4%
5Y CAGR
20.9%
7Y CAGR
17.2%
10Y CAGR
19.7%
Cash from Operating Activity Annual growth is higher than historical averages.
×